Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: cooperative events in tumorigenesis.

Since the discovery of the tumor suppressor p53 and the Ras oncogene, ample data have been accumulated, describing their aberrations in human cancer and their contribution to the multistep process of tumorigenesis. Several studies have also demonstrated that these dysregulated pathways cooperate to promote malignancy. Here we review recent studies on the cooperative molecular mechanisms by which p53 inactivation and oncogenic Ras converge to enhance tumorigenesis.

[1]  S. Lowe,et al.  Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. , 1998, Genes & development.

[2]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[3]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[4]  V. Rotter,et al.  Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. , 2005, Cancer research.

[5]  Toshimichi Yoshida,et al.  Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice , 2006, Oncogene.

[6]  A. Schetter,et al.  Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. , 2010, Carcinogenesis.

[7]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[8]  Paul Timpson,et al.  Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer , 2010, Proceedings of the National Academy of Sciences.

[9]  A. Levine,et al.  The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.

[10]  C. Der,et al.  Ras Family Signaling: Therapeutic Targeting , 2002, Cancer biology & therapy.

[11]  D. Woods,et al.  Regulation of the p53 pathway by Ras, the plot thickens. , 2001, Biochimica et biophysica acta.

[12]  A. Yakovlev,et al.  Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype , 2008, Nature.

[13]  B. Williams,et al.  A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. , 2006, Genes & development.

[14]  Rameen Beroukhim,et al.  An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB , 2010, Nature Medicine.

[15]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[16]  J. Kurie,et al.  A genetic mouse model for metastatic lung cancer with gender differences in survival , 2007, Oncogene.

[17]  D. Feldser,et al.  Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma , 2009, Nature.

[18]  V. Rotter,et al.  Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation , 1984, Nature.

[19]  Tsonwin Hai,et al.  Activating Transcription Factor 3, a Stress-inducible Gene, Suppresses Ras-stimulated Tumorigenesis* , 2006, Journal of Biological Chemistry.

[20]  V. Rotter,et al.  Activated p53 suppresses the histone methyltransferase EZH2 gene , 2004, Oncogene.

[21]  Varda Rotter,et al.  When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.

[22]  Judith Campisi,et al.  Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor , 2008, PLoS biology.

[23]  T. Jacks,et al.  Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase , 2009, Nature Protocols.

[24]  J. Yates,et al.  PRAK Is Essential for ras-Induced Senescence and Tumor Suppression , 2007, Cell.

[25]  N. Perkins,et al.  Integrating cell-signalling pathways with NF-κB and IKK function , 2007, Nature Reviews Molecular Cell Biology.

[26]  Hartmut Land,et al.  Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility , 2007, Nature Structural &Molecular Biology.

[27]  C. Y. Wang,et al.  Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. , 1997, Science.

[28]  V. Rotter,et al.  Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. , 2007, Cancer research.

[29]  V. Rotter,et al.  p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. , 2010, Cancer research.

[30]  V. Rotter,et al.  p53: balancing tumour suppression and implications for the clinic. , 2009, European journal of cancer.

[31]  P. Gruss,et al.  Participation of p53 cellular tumour antigen in transformation of normal embryonic cells , 1984, Nature.

[32]  J. Norman,et al.  Mutant p53 Drives Invasion by Promoting Integrin Recycling , 2009, Cell.